UNASSIGNED: 340 Background: Surgery alone rarely results in long-term disease-free control in @entity1 with N2 or N3 (stage III or IV) metastatic @entity5 . Five-year overall survival rarely exceeds 40% in this group of @entity1 . @entity1260 , @entity1311 , and @entity900 chemotherapy (ITP) has been reported in the neoadjuvant setting in a phase II trial. The evidence supporting adjuvant chemotherapy after inguinal lymph node dissection (LND) is poor. We report our experience of ITP chemotherapy given in the adjuvant setting after bilateral inguinal LND for stage III and IV @entity5 Methods: In our regional @entity5 center we performed a retrospective analysis of a prospectively maintained database of all @entity1 between May 2008 and February 2012 who received adjuvant chemotherapy for regional metastatic @entity5 . RESULTS: Four @entity1 received chemotherapy in the adjuvant setting. One @entity1 completed 4 cycles of @entity900 and @entity1487 after bilateral inguinal LND (pT1N2). There is no evidence of disease recurrence at 20 months post completion of chemotherapy. Three @entity1 received adjuvant chemotherapy with @entity1311 175 mg/m(2) on day 1; @entity1260 1,200 mg/m(2) on days 1-3; and @entity900 20 mg/m(2)on days 1-3 (ITP). All pts received 4 X 3 weekly cycles with no significant @entity137 . The first two @entity1 underwent inguinal LND for pT3N2 (stage IIIB) disease followed by 4 cycles of ITP. In both @entity1 surveillance imaging showed no evidence of disease recurrence 28 and 50 months, respectively, post completion of chemotherapy. The third @entity1 underwent inguinal LND for pT1bN3 (stage IV) disease followed by 4 cycles of ITP. Surveillance imaging at 6 months post completion of chemotherapy showed no evidence of local or distant recurrence. CONCLUSIONS: Multimodality treatment of regional metastatic @entity5 offers the best chance of long-term disease-free and overall survival. The ITP regimen is relatively nontoxic and well-tolerated. We propose that this regimen should be further investigated in the adjuvant or peri-operative settings.

Treatment of metastatic XXXX in the adjuvant setting with @entity1260 , @entity1311 , and @entity900 : A single institution experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['penile cancer', 'cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['Ifosfamide', 'ifosfamide'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-Fluorouracil']
@entity5 :: (MESH:D009369,Disease) :: ['penile cancer']
